Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Leptin administration Clear all
Completed Phase 4 Interventional Results available

A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa

NCT00140426
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Risperidone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

NCT05164341
View directory record Official record
Conditions
Partial Lipodystrophy
Interventions
metreleptin, Placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
12 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Sacramento, California • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 10, 2026, 5:45 PM EST
Recruiting No phase listed Observational

Lymphedema Surveillance Study

NCT02743858
View directory record Official record
Conditions
Breast Cancer, Lymphedema
Interventions
Bilateral arm measurements, Body mass index (BMI), Quality of Life Questionnaire, Blood draw
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

NCT04159415
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
Placebo, Low-Dose REGN4461, High-dose REGN4461
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Bethesda, Maryland • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 10, 2026, 5:45 PM EST
Completed No phase listed Observational Accepts healthy volunteers

The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment

NCT01067573
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Nov 10, 2026, 5:45 PM EST
Terminated Phase 2 Interventional Results available

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

NCT05088460
View directory record Official record
Conditions
Familial Partial Lipodystrophy, Metabolic Abnormalities
Interventions
REGN4461, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Boca Raton, Florida • Bethesda, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 10, 2026, 5:45 PM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Dihydroberberine Effects on Body Composition and Metabolic Health in Healthy Adults

NCT07322679
View directory record Official record
Conditions
Health Adult Subjects
Interventions
Placebo （Microcrystalline Cellulose）, Dihydroberberine（DHB）
Dietary Supplement
Lead sponsor
Nanjing Nutrabuilding Bio-tech Co., Ltd.
Other
Eligibility
35 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

In Vivo Leptin Signaling in Humans After Acute Leptin Administration

NCT01275053
View directory record Official record
Conditions
Lean, Obese, Obese Diabetics
Interventions
leptin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome

NCT00362440
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
Leptin, Pioglitazone or metformin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Nov 10, 2026, 5:45 PM EST
Terminated Phase 1 Interventional Results available

Effects of Metreleptin in Type 1 Diabetes Mellitus

NCT01268644
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Leptin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

NCT03013543
View directory record Official record
Conditions
Genetic Obesity, Obesity, Obesity Due to Melanocortin 4 Receptor Deficiency
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
43
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Nov 10, 2026, 5:45 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Increased Free Fatty Acids on Leptin Function

NCT01520454
View directory record Official record
Conditions
Obesity, Leptin Resistance
Interventions
Saline, Intralipid, Water, oral fat, Heparin
Drug · Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Nov 10, 2026, 5:45 PM EST
Completed No phase listed Observational

Pharmacodynamics of CNP During Growth Hormone Treatment

NCT01504802
View directory record Official record
Conditions
Pituitary Dwarfism, Idiopathic Short Stature
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Nov 10, 2026, 5:45 PM EST
Active, not recruiting Phase 2 Interventional Results available

Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

NCT00085982
View directory record Official record
Conditions
Severe Insulin Resistance
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 1Phase 2 Interventional Results available

A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks

NCT01832532
View directory record Official record
Conditions
Sleep Apnea, Sleep Disordered Breathing
Interventions
liraglutide
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional

Setmelanotide in a Single Patient With Partial Lipodystrophy

NCT03262610
View directory record Official record
Conditions
Hypertriglyceridemia, Obesity
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 15 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Nov 10, 2026, 5:45 PM EST
Completed Not applicable Interventional

Biomarkers in Obstructive Sleep Apnea Surgery

NCT00507078
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Surgical treatment for OSA
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics

NCT00634036
View directory record Official record
Conditions
Asthma
Interventions
pioglitazone, placebo
Drug
Lead sponsor
Fernando Holguin
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2Phase 3 Interventional Results available

Long Term Extension Trial of Setmelanotide

NCT03651765
View directory record Official record
Conditions
Obesity Associated With Defects in Leptin-melanocortin Pathway
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Chandler, Arizona • Scottsdale, Arizona • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Nov 10, 2026, 5:45 PM EST
Terminated Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

NCT00787644
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Nov 10, 2026, 5:45 PM EST
Completed Phase 2 Interventional Results available

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

NCT00140244
View directory record Official record
Conditions
HAART-induced Lipodystrophy and Metabolic Syndrome
Interventions
r-metHuLeptin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Nov 10, 2026, 5:45 PM EST